Robert Tyler earned his Doctorate in Physiology from Colorado State University specializing in cardiovascular studies of oxygen transport and aging. Dr. Tyler then received NIH and American Heart Association post-doctoral fellowships at the Cardiovascular Pulmonary Laboratory at the University of Colorado Health Sciences Center. There he pursued studies in identifying nitric oxide synthase transcription in pulmonary hypertension and developed models for liposomal gene transfection of nitric oxide synthase into the hypertensive pulmonary vasculature. He was appointed to Assistant Professor at the University of Colorado Denver teaching Physiology and conducting research in vascular reactivity and aging.
Dr. Tyler then joined Atrix Laboratories as a Clinical Scientist followed by appointment to Director Clinical Research focused on the development of Eligard (leuprolide acetate, s.c. depot delivery) for prostate cancer. He has also worked in Medical Affairs at Sanofi in cardiovascular and urology/oncology and Johnson & Johnson/Centocor in immunology/rheumatology.
Currently Dr. Tyler is a Medical Director at Dendreon with medical lead responsibilities for the PROCEED safety registry, STAND a sequencing study of androgen deprivation therapy and sipuleucel-T in non-metastatic, hormone-sensitive prostate cancer patients, PRIME an immune monitoring study further defining the mechanism of action of sipuleucel-T, and PREDICT a study to determine patient characteristics and biomarkers predictive of metastatic disease in M0 castration-resistant prostate cancer patients.